NOT FOR DISTRIBUTION, RELEASE OR REPUBLICATION, DIRECTLY OR INDIRECTLY, TO U.S.
NEWS WIRE SERVICES OR FOR DISSEMINATION IN OR INTO THE UNITED STATES, AUSTRALIA,
CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION, RELEASE OR
REPUBLICATION WOULD BE UNLAWFUL. 

Oslo, 24 March 2021:  Reference is made to the stock exchange notice issued on
24 February 2021 where Arctic Bioscience AS ("Arctic Bioscience" or the
"Company") announced the beginning of the stabilization period following a
private placement of new shares in the Company (the "Private Placement") and
admission to trading of the Company's shares on Euronext Growth Oslo (the
"Admission"). 

DNB Markets, a part of DNB Bank ASA ("DNB Markets"), acting as stabilization
manager has informed the Company that the stabilization period has ended.
Stabilization activities has been undertaken between 24 February 2021 and 24
March 2021 (the "Stabilization Period") and comprise a total of 1,451,612 shares
in the Company, purchased at an average price of NOK 28.0717, as further set out
in the attached end of stabilization notification.

As a consequence of the stabilization activities taken, DNB Markets has informed
the Company that it will not exercise the greenshoe option and shall redeliver
the 1,451,612 shares purchased through stabilization transactions to Capra
Invest AS and Ronja Capital II AS, in accordance with the terms of the share
lending agreement between the parties.

ABG Sundal Collier ASA and DNB Markets, part of DNB Bank ASA, acted as Joint
Global Coordinators and Joint Bookrunners in the Private Placement and as
Euronext Growth advisors in relation to the Admission (the "Managers"). Adviso
advokatfirma AS and Advokatfirmaet Wiersholm AS acted as legal counsels in
connection with the Private Placement and the Admission. 

For further information, please contact:
DNB Markets, a part of DNB Bank ASA
Aksel Thue
Tel: +47 23 26 81 01

This information is subject of the disclosure requirements pursuant to
Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 section 6 (3).

Click here for more information

© Oslo Bors ASA, source Oslo Stock Exchange